Travere Therapeutics, Inc.

TVTX • Biotechnology

$65.28

▼ -1.26 (-1.89%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$6.10B

Growth

—

Cash Flow

1/5

Trend

Volatile

Evidence

Positive revenue growth · 25.7%Positive free cash flow · 0.42Healthy liquidity · 2.74High debt level · 2.86Weak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 6, 2026, 12:42 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$65.28

Change-1.89%

Shares Out93.48M

Market Cap$6.10B

Enterprise Value$6.22B

52W Range15.60 - 66.24

Beta1.11

P/E-140.40

P/S10.32

P/B248.85

P/FCF-900.18

EV/Sales10.52

Price$65.28

Change-1.89%

Shares Out93.48M

Market Cap$6.10B

Enterprise Value$6.22B

52W Range15.60 - 66.24

Beta1.11

P/E-140.40

P/S10.32

P/B248.85

P/FCF-900.18

EV/Sales10.52

EV/EBITDA4,029.86

EV/FCF-917.85

Earnings Yield-0.71%

FCF Yield-0.11%

Dividend Yield0.00%

Gross Margin97.89%

Oper. Margin-12.80%

Profit Margin-5.21%

Debt/Eq2.86

Current Ratio2.74

Quick Ratio2.70

Target$65.80

Target Upside0.80%

Target Median$67.00

Target Range49.00 - 78.00

Volume6.31M

Avg Volume2.08M

EPS Surprise-0.09

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

58/100

Growth Potential

Revenue and expansion

95/100

Price Attractiveness

Cheap or expensive today

26/100

Why this score▼

Positive revenue growth · 25.7%Positive free cash flow · 0.42Healthy liquidity · 2.74High debt level · 2.86Weak profitability

Analyst view

Analyst sentiment and price target

TVTX

Analyst sentiment

Based on 18 analyst votes · 2026-09-05

92/100

Bullish

Hold

Bearish

Price Target

2026-08-07

Low

$49.00

Mean

$62.75

Median

$66.00

High

$70.00

Company Overview

IPO: 11/8/2012

Industry: Biotechnology

P/B i: 248.85

Debt / Equity i: 2.86

Operating Margin: -12.80%

Net Margin: -5.21%

ROE i: -

ROIC: -

Financial Health

Score12 / 20

Debt / Equity: 2.86

Current Ratio: 2.74

Quick Ratio: 2.70

Status: Good

Warnings

High debt level

Insider Transactions

Recent executive and insider activity

Inrig Jula

Transaction: 06/22/2026

SELL

Change

-468

Price

Not reported

Filing

06/22/2026

Type

SELL

Baynes Roy D.

Transaction: 06/12/2026

SELL

Change

-4,500

Price

$21.38

Filing

06/16/2026

Type

SELL

Baynes Roy D.

Transaction: 06/12/2026

SELL

Change

-4,500

Price

$50.00

Filing

06/16/2026

Type

SELL

Insider	Type	Change	Price	Transaction	Filing
Inrig Jula	SELL	-468	Not reported	06/22/2026	06/22/2026
Baynes Roy D.	SELL	-4,500	$21.38	06/12/2026	06/16/2026
Baynes Roy D.	SELL	-4,500	$50.00	06/12/2026	06/16/2026
Coughlin Timothy	SELL	-10,000	$26.52	06/12/2026	06/16/2026
Coughlin Timothy	SELL	-10,000	$50.07	06/12/2026	06/16/2026
Baynes Roy D.	BUY	+12,000	$42.26	05/19/2026	05/21/2026
Baynes Roy D.	BUY	+4,000	Not reported	05/19/2026	05/21/2026
Bruhn Suzanne Louise	BUY	+12,000	$42.26	05/19/2026	05/21/2026
Bruhn Suzanne Louise	BUY	+4,000	Not reported	05/19/2026	05/21/2026
Coughlin Timothy	BUY	+12,000	$42.26	05/19/2026	05/21/2026
Coughlin Timothy	BUY	+4,000	Not reported	05/19/2026	05/21/2026
LYONS GARY A	BUY	+12,000	$42.26	05/19/2026	05/21/2026
LYONS GARY A	BUY	+4,000	Not reported	05/19/2026	05/21/2026
Meckler Jeffrey A	BUY	+12,000	$42.26	05/19/2026	05/21/2026
Meckler Jeffrey A	BUY	+4,000	Not reported	05/19/2026	05/21/2026
Orwin John A	BUY	+12,000	$42.26	05/19/2026	05/21/2026
Orwin John A	BUY	+4,000	Not reported	05/19/2026	05/21/2026
Poole Sandra	BUY	+12,000	$42.26	05/19/2026	05/21/2026
Poole Sandra	BUY	+4,000	Not reported	05/19/2026	05/21/2026
Squarer Ron	BUY	+12,000	$42.26	05/19/2026	05/21/2026

About the Company

Travere Therapeutics, Inc.

Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.

Source - link

Peers

AAPG APGE CELC CGON CNTA IRON LEGN RARE TARS XENE

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Artia Global Partners LP Buys New Shares in Travere Therapeutics, Inc. $TVTX

Artia Global Partners LP purchased a new stake in Travere Therapeutics, Inc. (NASDAQ: TVTX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 339,033 shares of the company's stock, valued at approximately $19,260,000. Travere Therapeutics accounts for about 3.6% of

Defense World

Travere Therapeutics: Valuation Suggests A Buy

Travere Therapeutics is rated Buy, with a DCF-based fair value of ~$81 per share, implying 27% upside. FILSPARI's commercial ramp is strong, posting $141.1M in Q2 U.S. sales and targeting a $3B+ peak sales opportunity across IgAN and FSGS. My model assumes modest FILSPARI penetration, conservative pricing, and accounts for royalty burdens, tax credits, and IP risks.

Seeking Alpha

Everest Medicines Reports 1H 2026 Results, Enters New Phase as Growth Accelerates and Innovation Gains Momentum

HONG KONG, Aug 19, 2026 - (ACN Newswire) - Everest Medicines (01952.HK) announced its interim results for the six months ended June 30, 2026. Everest delivered

GuruFocus

Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline

Travere Therapeutics NASDAQ: TVTX is pursuing growth through expanded use of FILSPARI in rare kidney diseases while advancing a late-stage treatment candidate for classical homocystinuria and building its renal pipeline through the recently in-licensed BTK inhibitor civorebrutinib, Chief Financial Officer Chris Cline said at a Canaccord Genuity discussion.

MarketBeat

Bank of America Corp DE Trims Position in Travere Therapeutics, Inc. $TVTX

Bank of America Corp DE lessened its holdings in shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) by 27.8% in the quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,345,111 shares of the company's stock after selling 517,244 shares

Defense World

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-04	-0.3	-0.39	-0.09
2026-02-19	0.03	0.03	0
2025-10-30	-0.31	0.28	0.59
2025-08-06	-0.28	-0.14	0.14
2025-05-01	-0.55	-0.47	0.08
2025-02-20	-0.58	-0.73	-0.15
2024-10-31	-0.7	-0.7	0
2024-08-01	-0.87	-0.9	-0.03
2024-05-06	-0.98	-1.76	-0.78
2024-02-15	-1.27	-1.16	0.11
2023-11-07	-1.09	-1.17	-0.08
2023-08-03	-1.16	-1.13	0.03